ibrutinib,zilovertamab
oncternal therapeutics,abbvie,janssen
['mantle,(-dismantle)', 'zilovertamab', ' ibru', 'lymphoma', 'lymsm']
ror1 inhibitor zilovertamab in combination with ibrutinib showing promising efficacy in r/r mantle-cell lymphoma #ash22 #lymsm 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer